Quick Answer
OnKure Therapeutics, Inc. reported Operating Income of -$62.95 million for fiscal year 2025.
OnKure Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$62.95M | -15.7% |
| 2024 | -$54.39M | -47.3% |
| 2023 | -$36.93M | +31.4% |
| 2022 | -$53.85M | -35.2% |
| 2021 | -$39.82M | -103.7% |
| 2020 | -$19.55M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$15.50M | -34.7% | +5.0% |
| June 30, 2025 | -$16.32M | -13.8% | +4.0% |
| March 31, 2025 | -$17.00M | -72.9% | -47.7% |
| September 30, 2024 | -$11.51M | +44.9% | +19.7% |
| June 30, 2024 | -$14.34M | +31.8% | -45.9% |
| March 31, 2024 | -$9.83M | +39.0% | +52.9% |
| September 30, 2023 | -$20.89M | -50.9% | +0.7% |
| June 30, 2023 | -$21.04M | -69.2% | -30.5% |
- OnKure Therapeutics, Inc. showed a decrease of -15.7% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, OnKure Therapeutics, Inc.’s operating income has declined by 222.0% (from -$19.55 million to -$62.95 million).
- The most recent figure is from OnKure Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: